Different origin and dispersal of sulfadoxine-resistant Plasmodium falciparum haplotypes between Eastern Africa and Democratic Republic of Congo
Introduction
The widespread emergence of Plasmodium falciparum resistance to antimalarial drugs is a major public health concern threatening malaria control efforts. Sulfadoxine/pyrimethamine (SP) and amodiaquine were adopted to replace chloroquine as the first-line treatment against uncomplicated malaria following widespread resistance to chloroquine [1]. However, a few years after the adoption of SP, escalating treatment failure rates indicated that SP resistance was spreading. This prompted policy changes to adopt artemisinin-based combination therapies (ACTs) as the first-line treatment in malaria-endemic countries in Africa.
SP is still recommended by the World Health Organization (WHO) in sub-Saharan Africa for intermittent preventive treatment during pregnancy (IPTp-SP) to protect women and to improve foetal outcomes against the consequences of malaria infection. It is also used in seasonal malaria chemoprevention (SMC) strategies in combination with amodiaquine in areas prone to high seasonal malaria transmission across the Sahel subregion as well as in intermittent preventive treatment in infants (IPTi-SP) in areas of moderate to high transmission [2], [3]. In some countries (including the Democratic Republic of the Congo), SP is used in combination with artemisinin for the treatment of uncomplicated malaria [4]. However, due to widespread SP resistance, concerns have been raised about whether this strategy is still effective [5], [6].
Pyrimethamine resistance is conferred by point mutations in the P. falciparum dihydrofolate reductase (Pfdhfr) gene leading to substitutions at codons N51I, C59R and S108N [7]. Sulfadoxine resistance is mediated by substitutions in the P. falciparum dihydropteroate synthetase (Pfdhps) at codons S/A436F, A437G, K540E, A581G and A613S/T [8], [9]. Evidence suggests that SP resistance tends to increase as a result of stepwise accumulation of single nucleotide polymorphisms (SNPs) in the Pfdhps–Pfdhfr genes [10]. Interestingly, parasite isolates from East Africa were shown to harbour Pfdhps haplotypes with double mutations (at codons A437G and K540E) leading to the SGEAA haplotype, whereas in Western African countries the mutations are mainly limited to a single A437G mutation [11], [12]. Recently, in East Africa, expansion of Pfdhps mutation at codons A581G and K540E has worsened SP resistance leading to the emergence of the triple-mutant haplotype (SGEGA) [13]. Pfdhfr–Pfdhps haplotypes confer high-grade resistance associated with poor outcomes of IPTp-SP [6], [14]. Recently, a Pfdhps sextuple haplotype, defined as a combination of the triple Pfdhfr and triple Pfdhps mutations, was associated with reduced birth weight [6]. In addition, a recent meta-analysis estimated that if the prevalence of Pfdhps 581G is >10.1%, then IPTp-SP is no longer protective against low birth weight and alternative strategies should be considered [15]. In the East African region where the levels of SGEAA and SGEGA haplotypes are expanding, the effectiveness of IPTp-SP in controlling parasite growth and improving pregnancy outcomes is deteriorating [6], [14], [15]. In contrast, in West Africa, the majority of haplotypes are either Pfdhps wild-type or a single A437G (SGKAA) or S436A (AAKAA) mutation, with limited occurrence of the K540E and A581G mutants, and thus IPTp-SP retains its effectiveness [11]. These observations underscore the need for monitoring the distribution of parasite populations in order to mitigate the dispersal of resistant haplotypes in the region.
Studies from Southeast Asia revealed multiple and limited origins of Pfdhps mutant alleles [16], [17], and analysis of the Pfdhps mutant alleles in malaria parasites from East and West Africa demonstrated that resistance emerged independently in multiple sites in Africa [17]. After segregating the Pfdhps triple mutant SGEG haplotype lineages by country, the Pfdhps haplotypes seemed of local origin [18]. In DR Congo, Taylor et al [19] demonstrated genetically distinct resistant Pfdhps haplotypes between Eastern and Western provinces. However, owing to the escalating levels of Pfdhps A581G and K540E mutations associated with poor IPTp outcomes in Eastern Africa, there is a need to define the genetic structure and dispersal of Pfdhps haplotypes in the Central African corridor and their relatedness to the Eastern African lineages. Therefore, this study determined the origin and dispersal of sulfadoxine-resistant lineages in Central Africa compared with Eastern Africa Pfdhps haplotypes.
Section snippets
Sample collection
Samples for this study were collected between 2012 and 2014 in Uganda (Kihurura) and DR Congo (Lisungi-Kinshasa) as part of the QuinACT clinical trial [20]. Samples from Tanzania were collected in 2014 in Muheza District, Tanga Region, as part of a study to assess the efficacy and safety of artemether/lumefantrine versus dihydroartemisinin/piperaquine for the treatment of uncomplicated malaria (Fig. 1). Children aged 6 months to 10 years with uncomplicated falciparum malaria were enrolled.
Frequency and pattern of Pfdhps single nucleotide polymorphism haplotypes
A total of 264 samples were analysed for Pfdhps SNPs at codons 436, 437, 540, 581 and 613. Of these, 140 samples could be constructed into haplotypes, as the rest were mixed infections at one or more of the Pfdhps SNPs; DR Congo, n = 37; Tanzania, n = 41; and Uganda, n = 62. In total, six Pfdhps SNP haplotypes were detected: SAKAA (wild-type); SGKAA, AGKAA and SAEAA (single mutants); and SGEAA and SAEGA (double mutants); and SGEGA (triple mutant) (Fig. 2). The pattern varied, with single-mutant
Discussion
Molecular analysis of Pfdhps revealed a high presence of double (SGEAA) and triple (SGEGA) mutant haplotypes predominantly in the East African region (Tanzania and Uganda), whilst in DR Congo the single Pfdhps mutants were predominant. In contrast, the frequency of the Pfdhps SGEGA observed was somewhat low compared with recent studies in the same area of Northern Eastern Tanzania [32]. Nonetheless, the level of the Pfdhps triple mutation correlated with the increasing level of Pfdhps A581G
Conclusion
In Uganda and Tanzania, gene flow patterns contribute the dispersal and shared the origin of parasites carrying double- and triple-mutant Pfdhps haplotypes associated with poor IPTp-SP outcomes. However, the origins of the Pfdhps haplotypes in DR Congo and Eastern Africa sites are different. The genetic structure demonstrated a divergent and distinct population cluster predominated by single-mutant Pfdhps haplotypes in the DR Congo site. This reflects the limited dispersal of double- and
Acknowledgements
The study participants are thanked for agreeing to take part in this study. NIMR Tanga (Tanzania) staff involved in the WB project are thanked for their role in field sample collection. This work would not have been possible without the medical and study team involved in the QuinACT trial at Lisungi Health Centre (DR Congo) and Kihuru Kazo Health Centre (Uganda). Ulla Abildtrup at the Centre for Medical Parasitology (Copenhagen, Denmark) is thanked for the technical support during the
References (46)
- et al.
Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria
Trends Parasitol
(2013) - et al.
Antifolate antimalarial resistance in southeast Africa: a population-based analysis
Lancet
(2003) - et al.
High prevalence of sulphadoxine–pyrimethamine resistance-associated mutations in Plasmodium falciparum field isolates from pregnant women in Brazzaville, Republic of Congo
Infect Genet Evol
(2015) - et al.
Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum
Nature
(2002) Seasonal malaria chemoprevention (SMC) for Plasmodium falciparum control in highly seasonal transmission areas of Sahel sub-region in Africa
(2013)WHO policy recommendation on intermittent preventive treatment during infancy with sulfadoxine–pyrimethamine (IPTi-SP) for Plasmodium falciparum malaria control in Africa
(2010)Guidelines for the treatment of malaria
(2015)- et al.
Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy
Trop Med Int Health
(2011) - et al.
Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania
Emerg Infect Dis
(2013) - et al.
Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase–thymidylate synthase gene of Plasmodium falciparum
Proc Natl Acad Sci USA
(1988)
Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine
Eur J Biochem
Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum
Proc Natl Acad Sci USA
Ordered accumulation of mutations conferring resistance to sulfadoxine–pyrimethamine in the Plasmodium falciparum parasite
J Infect Dis
High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at codon 581
PLoS ONE
Independent origin of Plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia
Emerg Infect Dis
Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring
PLoS ONE
Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis
Trop Med Int Health
Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations
J Infect Dis
Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria
PLoS Med
Independent lineages of highly sulfadoxine-resistant Plasmodium falciparum haplotypes, Eastern Africa
Emerg Infect Dis
Plasmodium falciparum sulfadoxine resistance is geographically and genetically clustered within the DR Congo
Sci Rep
Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial
Trials
A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology
Am J Trop Med Hyg
Cited by (10)
Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo
2024, International Journal of Infectious DiseasesEvaluation of the usefulness of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a context with increased resistance of Plasmodium falciparum in Kingasani Hospital, Kinshasa in the Democratic Republic of Congo
2021, Infection, Genetics and EvolutionCitation Excerpt :It would therefore be speculative to imagine the presence or absence of other mutations that were not analyzed (e.g., dhps I431V and A581G). However, though the prevalence of dhps A581G is expected to be lower in Kinshasa than in East Africa, we acknowledge that this specific mutation is worth being investigated in future given its clinical relevance for IPTp-SP failures and the growing concern raised by its emergence in other regions of Africa (Baraka et al., 2017; Mandoko et al., 2018; Minja et al., 2013; van Eijk et al., 2019). Secondly, the survey could not avoid the potential information and memory biases inherent in any self-reporting of information, even if the use of medical files and ANC booklets could have reduced these biases.
Molecular epidemiology and evolution of drug-resistant genes in the malaria parasite Plasmodium falciparum in southwestern Nigeria
2018, Infection, Genetics and EvolutionCitation Excerpt :Interestingly, about 12% of the haplotypes (of the Pfdhps gene), although in a low frequency, are restricted to one of the other population and are thus considered to be particular to that population. In line with this study is the detection of some of the Pfdhps haplotypes (IAGKAA, ISGKAA, IAAKAA, ISAKAA, ISGKGA, IAGKAS, IAGKGA, IAGKGS, VAGKAS, VAGKGS and VAGKGA) from previous studies conducted in Democratic Republic of Congo, Tanzania as well as in India (Baraka et al., 2017; Oguike et al., 2016; Minja et al., 2013). Only four haplotypes (two wild and two mutant, two in Pfcrt and one each in Pfdhfr and Pfdhps) were found to be highly prevalent in the southern part of Nigeria with a minimum frequency of 25% (Pfdhps - ISGKAA in Edo) to >45% for Pfdhfr (AIRNI in Lagos).
High prevalence of Plasmodium falciparum antimalarial drug resistance markers in isolates from asymptomatic patients from the Republic of the Congo between 2010 and 2015
2018, Journal of Global Antimicrobial ResistanceCitation Excerpt :The four mutations S436A, A437G, K540E and A581G have been found among samples from asymptomatic pregnant women in the south of the Republic of the Congo [36]. These same mutations were found in the neighbouring Democratic Republic of the Congo [53,54], whereas the K540E mutation is rare and A581G is completely absent in Gabon, its other neighbouring country [17,55]. The A613S mutation is rare in Africa and was not observed [13,56,57].
- 1
These two authors contributed equally to this work.